The significance of monoclonal gammopathy of undetermined significance

Haematologica

Volumn 94, Issue 12, 2009, Pages 1641-1644

  Kyle, Robert A ^a   Kumar, Shaji ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON DISULFIDE; CARBON TETRACHLORIDE; CHLOROTHALONIL; DIELDRIN; FUNGICIDE; HERBICIDE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INSECTICIDE; M PROTEIN; PESTICIDE;

AGE DISTRIBUTION; AMYLOIDOSIS; ATOMIC BOMB; CANCER PREVENTION; CANCER RISK; CANCER SUSCEPTIBILITY; CAUSE OF DEATH; CHROMOSOME TRANSLOCATION; DISEASE COURSE; EDITORIAL; ENVIRONMENTAL FACTOR; GENETIC PREDISPOSITION; HUMAN; LYMPHOPROLIFERATIVE DISEASE; MONOCLONAL IMMUNOGLOBULINEMIA; MORTALITY; MULTIPLE MYELOMA; PLASMA CELL; PLASMA CELL DYSCRASIA; PREVALENCE; PROPHYLAXIS; PROTEIN BLOOD LEVEL; RACE DIFFERENCE; RADIATION EXPOSURE; SEX RATIO; SURVIVAL TIME; WALDENSTROEM MACROGLOBULINEMIA;

CAUSE OF DEATH; HUMANS; MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE; RISK FACTORS; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 73149115752     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.013961     Document Type: Editorial

References (22)

1. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003; 121:749-57.
2. Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 2006;354:1362-9.
3. Kyle RA, Therneau TM, Melton LJ III, Dispenzieri A, Larson D, Benson J, et al. Monoclonal gammopathy of undetermined significance: estimated incidence and duration prior to recognition. Blood 2007;110:79a (Abstract #246).
4. Cohen HJ, Crawford J, Rao MK, Pieper CF, Currie MS. Racial differences in the prevalence of monoclonal gammopathy in a community-based sample of the elderly.[erratum in Am J Med 1998;105:362]. Am J Med 1998;104:439-44.
5. Singh J, Dudley AW Jr, Kulig KA. Increased incidence of monoclonal gammopathy of undetermined significance in blacks and its age-related differences with whites on the basis of a study of 397 men and one woman in a hospital setting. J Lab Clin Med 1990;116:785-9.
6. Landgren O, Katzmann JA, Hsing AW, Pfeiffer RM, Kyle RA, Yeboah ED, et al. Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana. Mayo Clin Proc 2007;82:1468-73.
7. Iwanaga M, Tagawa M, Tsukasaki K, Kamihira S, Tomonaga M. Prevalence of monoclonal gammopathy of undetermined significance: study of 52,802 persons in Nagasaki City, Japan. Mayo Clin Proc 2007;82:1474-9.
8. Landgren O, Kyle RA, Hoppin JA, Beane Freeman LE, Cerhan JR, Katzmann JA, et al. Pesticide exposure and risk of monoclonal gammopathy of undetermined significance in the Agricultural Health Study. Blood 2009;113:6386-91.
9. Vachon CM, Kyle RA, Therneau TM, Foreman BJ, Larson DR, Colby CL, et al. Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance. Blood 2009;114:785-90.
10. Kyle RA. Monoclonal gammopathy of undetermined significance: natural history in 241 cases. Am J Med 1978;64:814-26.
11. Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Melton LJ, III. Long-term follow-up of 241 patients with monoclonal gammopathy of undetermined significance: the original Mayo Clinic series 25 years later. Mayo Clin Proc 2004;79:859-66.
12. Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 2002;346:564-9.
13. Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003;78:21-33.
14. Landgren O, Kyle RA, Pfeiffer RM, Katzmann JA, Caporaso NE, Hayes RB, et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 2009;113:5412-7.
15. Weiss BM, Abadie J, Verma P, Howard RS, Kuehl WM. A monoclonal gammopathy precedes multiple myeloma in most patients. Blood 2009;113:5418-22.
16. Kristinsson SY, Bjorkholm M, Andersson TM, Eloranta S, Dickman PW, Goldin LR, et al. Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined significance: a population-based study. Haematologica 2009;94:1714-20.
17. Kyle RA, Rajkumar SV. Monoclonal gammopathies of undetermined significance: a review. Immunol Rev 2003;194:112-39.
18. van de Poel MH, Coebergh JW, Hillen HF. Malignant transformation of monoclonal gammopathy of undetermined significance among out-patients of a community hospital in southeastern Netherlands. Br J Haematol 1995;91:121-5.
19. Schaar CG, le Cessie S, Snijder S, Franck PF, Wijermans PW, Ong C, et al. Long-term follow-up of a population based cohort with monoclonal proteinaemia. Br J Haematol 2009; 144:176-84.
20. Gregersen H, Ibsen J, Mellemkjoer L, Dahlerup J, Olsen J, Sorensen H. Mortality and causes of death in patients with monoclonal gammopathy of undetermined significance. Br J Haematol 2001;112:353-7.
21. Anderson KC, Kyle RA, Rajkumar SV, Stewart AK, Weber D, Richardson P. Clinically relevant end points and new drug approvals for myeloma. Leukemia 2008;22:231-9.
22. Kyle RA, Rajkumar SV. Epidemiology of the plasma-cell disorders. Best Pract Res Clin Haematol 2007;20:637-64.